Novartis says it's not interested in merging with another Big Pharma player--but CEO Daniel Vasella (photo) still won't comment on a rumored takeover of German rival Bayer.
Vasella told a French newspaper that a merger isn't the answer to the company's skyrocketing R&D costs and less-than-skyrocketing revenues. But when asked point-blank about Bayer, he clammed up. Some stock analysts have pooh-poohed the notion of Novartis snapping up Bayer. Others, however, helped fuel the rumors, which have died down a bit lately. Vasella's "no comment" just may stir them up again.Â
- read the coverage from Forbes
Related Articles:
Rumor Mill: Novartis may bid for Bayer. Report
Cash-rich Novartis CEO mulls biotech buyouts. Report
Bayer plans to beef up biotech pipeline. Report
Novartis CEO critiques U.S. healthcare. Report